弥漫性大B细胞淋巴瘤一线免疫化疗后复发/难治的分子遗传学因素研究进展
Advances in molecular genetic factors of relapse/refractory diffuse large B-cell lymphoma after first-line immunochemotherapy
宁夏 1朱尊民1
作者信息
- 1. 河南大学人民医院河南省人民医院血液内科河南省人民医院血液病研究所,河南郑州 450003
- 折叠
摘要
弥漫性大B细胞淋巴瘤具有高度异质性,不同个体的临床特征、遗传学改变、免疫表型等存在差异,对免疫化疗方案的反应也不相同.多数弥漫性大B细胞淋巴瘤患者一线应用R-CHOP(利妥昔单抗+环磷酰胺+多柔比星+长春新碱+泼尼松)方案治疗可获得长期生存,但30％～40％的患者出现复发/难治.本研究就弥漫性大B细胞淋巴瘤的分子分型、一线免疫化疗后复发/难治相关基因突变的研究进展作一综述.
Abstract
Diffuse large B-cell lymphoma is a highly heterogeneous tumor with different clinical features,genetic changes,immunophenotypes,and responses to immunochemotherapy regimen.The first-line treatment with R-CHOP(rituximab+cyclophosphamide+doxorubicin+vinnestine+prednisone)can achieve a long survival in most patients with diffuse large B-cell lymphoma,but relapse/refractory would develop in 30％to 40％of patients.This paper reviews the research progress of the molecular typing of diffuse large B-cell lymphoma and the progress of relapse/refractory related gene mutations after first-line immunochemotherapy.
关键词
弥漫性大B细胞淋巴瘤/免疫化疗/复发/难治/分子遗传学Key words
diffuse large B-cell lymphoma/immunochemotherapy/relapse/refractory/molecular genetics引用本文复制引用
基金项目
河南省2023年科技发展计划(232102310003)
出版年
2024
NETL
NSTL
万方数据